These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30673883)

  • 1. Predictive markers for MGMT promoter methylation in glioblastomas.
    Kanazawa T; Minami Y; Jinzaki M; Toda M; Yoshida K; Sasaki H
    Neurosurg Rev; 2019 Dec; 42(4):867-876. PubMed ID: 30673883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
    Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
    J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
    Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
    Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma.
    Kanas VG; Zacharaki EI; Thomas GA; Zinn PO; Megalooikonomou V; Colen RR
    Comput Methods Programs Biomed; 2017 Mar; 140():249-257. PubMed ID: 28254081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
    Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
    Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
    Uno M; Oba-Shinjo SM; Camargo AA; Moura RP; Aguiar PH; Cabrera HN; Begnami M; Rosemberg S; Teixeira MJ; Marie SK
    Clinics (Sao Paulo); 2011; 66(10):1747-55. PubMed ID: 22012047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C; Wang Q; Yan X; Wang J
    Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
    Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
    Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
    Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
    Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.
    Korfiatis P; Kline TL; Coufalova L; Lachance DH; Parney IF; Carter RE; Buckner JC; Erickson BJ
    Med Phys; 2016 Jun; 43(6):2835-2844. PubMed ID: 27277032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.